肝胆疾病发病机制与治疗学进展II
Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases II.
作者信息
Wang Jing-Hua
机构信息
Institute of Oriental Medicine, Dongguk University, 32 Dongguk-ro, Goyang 10326, Republic of Korea.
出版信息
Biomedicines. 2025 Apr 8;13(4):904. doi: 10.3390/biomedicines13040904.
Abstract
Hepatobiliary diseases, including liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and cholestatic liver disorders, pose significant global health challenges due to their complex pathogenesis and limited treatment options [...].
摘要
肝胆疾病，包括肝纤维化、肝硬化、肝细胞癌（HCC）和胆汁淤积性肝病，因其发病机制复杂且治疗选择有限，对全球健康构成了重大挑战[...]。
相似文献
1
Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases II.肝胆疾病发病机制与治疗学进展II
Biomedicines. 2025 Apr 8;13(4):904. doi: 10.3390/biomedicines13040904.
2
Optimization of hepatobiliary phase delay time of Gd-EOB-DTPA-enhanced magnetic resonance imaging for identification of hepatocellular carcinoma in patients with cirrhosis of different degrees of severity.优化钆塞酸二钠增强磁共振成像肝胆期延迟时间，以识别不同严重程度肝硬化患者的肝细胞癌。
World J Gastroenterol. 2018 Jan 21;24(3):415-423. doi: 10.3748/wjg.v24.i3.415.
3
Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development.肝胆磁共振成像的影像学特征与肝细胞癌发展的风险。
Scand J Gastroenterol. 2022 Dec;57(12):1470-1477. doi: 10.1080/00365521.2022.2093124. Epub 2022 Jul 4.
4
Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients.高尔基体蛋白73：一种用于评估肝病患者肝硬化及预后的生物标志物。
World J Gastroenterol. 2020 Sep 14;26(34):5130-5145. doi: 10.3748/wjg.v26.i34.5130.
5
Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis.可溶性Axl是肝硬化和肝细胞癌发展的准确生物标志物：一项大规模多中心分析的结果
Oncotarget. 2017 Jul 11;8(28):46234-46248. doi: 10.18632/oncotarget.17598.
6
Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.钆塞酸增强肝脏磁共振成像在检测 HCC 和根据米兰标准和 UNOS 指南分配肝移植受者中的诊断性能：与组织病理学发现的相关性。
Radiology. 2015 Jan;274(1):149-60. doi: 10.1148/radiol.14140141. Epub 2014 Sep 5.
7
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.慢性肝胆疾病的当前治疗方案及有前景的分子疗法
Biomolecules. 2025 Jan 14;15(1):121. doi: 10.3390/biom15010121.
8
Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma.肝纤维化、肝硬化和肝细胞癌中肝窦内皮细胞的细胞间串扰
Dig Liver Dis. 2022 May;54(5):598-613. doi: 10.1016/j.dld.2021.07.006. Epub 2021 Jul 31.
9
Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.利用动物模型研究非酒精性脂肪性肝炎相关的肝细胞癌。
Oncotarget. 2016 Jul 5;7(27):42762-42776. doi: 10.18632/oncotarget.8641.
10
Hepatobiliary disease in patients with cystic fibrosis.囊性纤维化患者的肝胆疾病
Curr Opin Gastroenterol. 2009 May;25(3):272-8. doi: 10.1097/MOG.0b013e3283298865.
本文引用的文献
1
Liver diseases: epidemiology, causes, trends and predictions.肝脏疾病：流行病学、病因、趋势及预测
Signal Transduct Target Ther. 2025 Feb 5;10(1):33. doi: 10.1038/s41392-024-02072-z.
2
Gut microbiota in health and disease: advances and future prospects.健康与疾病中的肠道微生物群：进展与未来展望。
MedComm (2020). 2024 Nov 20;5(12):e70012. doi: 10.1002/mco2.70012. eCollection 2024 Dec.
3
Single and Mixed Strains of Probiotics Reduced Hepatic Fat Accumulation and Inflammation and Altered Gut Microbiome in a Nonalcoholic Steatohepatitis Rat Model.益生菌单菌株和混合菌株可减少非酒精性脂肪性肝炎大鼠模型中的肝脏脂肪堆积和炎症，并改变肠道微生物群。
Biomedicines. 2024 Aug 14;12(8):1847. doi: 10.3390/biomedicines12081847.
4
Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma.肠道微生物群、免疫紊乱与肝细胞癌
Biomedicines. 2024 Aug 7;12(8):1797. doi: 10.3390/biomedicines12081797.
5
Angiographic Aspects of Transarterial Radioembolization: A Comparison of Technical Options to Avoid Extrahepatic Microsphere Depositions.经动脉放射性栓塞的血管造影表现：避免肝外微球沉积的技术选择比较
Biomedicines. 2024 Aug 7;12(8):1794. doi: 10.3390/biomedicines12081794.
6
Updated Insights into Probiotics and Hepatobiliary Diseases.益生菌与肝胆疾病的最新见解
Biomedicines. 2024 Feb 25;12(3):515. doi: 10.3390/biomedicines12030515.
7
Bile Acid Sequestration via Colesevelam Reduces Bile Acid Hydrophobicity and Improves Liver Pathology in Mice with a Human-like Bile Acid Composition.通过考来维仑进行胆汁酸螯合可降低胆汁酸疏水性并改善具有类人胆汁酸组成的小鼠的肝脏病理状况。
Biomedicines. 2023 Sep 8;11(9):2495. doi: 10.3390/biomedicines11092495.
8
Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer.钬-166微球经动脉放射性栓塞术（TARE）在原发性和继发性肝癌患者多学科肿瘤治疗中的临床结果
Biomedicines. 2023 Jun 26;11(7):1831. doi: 10.3390/biomedicines11071831.
9
-Fermented Ameliorates Metabolic-Syndrome-Like Pathological Conditions in Long-Term HFHFD-Fed Mice.发酵物改善长期高脂高糖饮食喂养小鼠的类似代谢综合征的病理状况。
Antioxidants (Basel). 2022 Nov 15;11(11):2254. doi: 10.3390/antiox11112254.
10
Combination of and Metformin Ameliorates Diet-Induced Metabolic Dysregulation in Mice via the Gut-Liver-Brain Axis.联合 和二甲双胍通过肠道-肝脏-大脑轴改善小鼠饮食诱导的代谢失调。
Am J Chin Med. 2020;48(6):1409-1433. doi: 10.1142/S0192415X2050069X. Epub 2020 Sep 9.
Zotero 插件